MCID: PTT008
MIFTS: 46

Pituitary Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Pituitary Carcinoma

MalaCards integrated aliases for Pituitary Carcinoma:

Name: Pituitary Carcinoma 12 20 58 6 15 71
Pituitary Cancer 20 17
Malignant Neoplasm of Pituitary Gland 71
Carcinoma of the Pituitary Gland 12

Characteristics:

Orphanet epidemiological data:

58
pituitary carcinoma
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:4916
MeSH 44 D010911
NCIt 50 C4536
SNOMED-CT 67 128665000
ICD10 32 C75.1
ICD10 via Orphanet 33 C75.1
UMLS via Orphanet 72 C0346300
Orphanet 58 ORPHA300385
UMLS 71 C0346300 C0496842

Summaries for Pituitary Carcinoma

MalaCards based summary : Pituitary Carcinoma, also known as pituitary cancer, is related to hormone producing pituitary cancer and prolactin producing pituitary tumor. An important gene associated with Pituitary Carcinoma is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Peptide ligand-binding receptors and Relaxin signaling pathway. Affiliated tissues include pituitary, thyroid and spinal cord, and related phenotypes are pituitary carcinoma and headache

Related Diseases for Pituitary Carcinoma

Diseases related to Pituitary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 307)
# Related Disease Score Top Affiliating Genes
1 hormone producing pituitary cancer 31.2 SSTR2 SST PRL POMC GNAS GHRH
2 prolactin producing pituitary tumor 30.9 PRL POMC MGMT GHRH
3 pituitary tumors 30.8 SST PRL POMC GNAS
4 non-functioning pituitary adenoma 30.4 SST MUC1
5 cauda equina syndrome 30.3 POMC GFAP
6 amenorrhea 30.1 PRL POMC CRH
7 multiple endocrine neoplasia 30.1 SST POMC GNAS CHGA
8 diabetes insipidus 30.1 PRL POMC CRH
9 chromophobe adenoma 30.1 PRL POMC
10 neuroendocrine tumor 30.0 SSTR2 SST POMC GHRH CHGA
11 myoepithelial carcinoma 30.0 TP53 MUC1 GFAP
12 paraganglioma 30.0 SST GFAP CHGA
13 in situ carcinoma 29.9 TP53 MUC1 BRCA2
14 hypopituitarism 29.8 PRL POMC GHRH CRH
15 pituitary apoplexy 29.7 SST PRL POMC
16 hyperprolactinemia 29.6 SST PRL POMC GNAS GHRH
17 glomus tumor 29.6 TP53 MUC1 CHGA
18 pleomorphic adenoma 29.5 TP53 MUC1 GFAP
19 pituitary adenoma 29.5 SSTR2 SST PRL POMC MEG3 GNAS
20 acromegaly 29.4 SSTR2 SST PRL POMC GNAS GHRH
21 multiple endocrine neoplasia, type i 29.4 SST PRL POMC GNAS GHRH CHGA
22 meningioma, familial 29.3 TP53 SSTR2 SST MUC1 MEG3 GFAP
23 pituitary adenoma, prolactin-secreting 29.3 SSTR2 SST PRL POMC MIR93 GNAS
24 hyperthyroidism 29.1 THRB SST PRL POMC GNAS
25 nelson syndrome 29.1 SST PRL POMC MGMT CRH
26 lynch syndrome 29.0 TP53 PMS2 MGMT BRCA2
27 hypothyroidism 28.9 THRB SST PRL POMC GNAS GHRH
28 pheochromocytoma 28.9 SST PRL POMC MEG3 CRH CHGA
29 functioning pituitary adenoma 28.7 SSTR2 SST PRL POMC MUC1 MIR93
30 adenoma 28.3 TP53 SSTR2 SST PRL POMC MUC1
31 acth-secreting pituitary adenoma 28.2 SSTR2 SST PRL POMC MIR93 MGMT
32 bronchial adenomas/carcinoids childhood 10.4 SST POMC
33 chiasmal syndrome 10.4 SST POMC
34 bap1 tumor predisposition syndrome 10.4 PMS2 BRCA2
35 acth-independent macronodular adrenal hyperplasia 1 10.4 POMC GNAS
36 appendix carcinoid tumor 10.4 PMS2 CHGA
37 gastrointestinal neuroendocrine benign tumor 10.4 SST CHGA
38 ampulla of vater neoplasm 10.4 SST CHGA
39 type c thymoma 10.4 SSTR2 SST
40 carotid body cancer 10.4 SST CHGA
41 non-functioning pancreatic endocrine tumor 10.4 SST CHGA
42 duodenal benign neoplasm 10.4 SST CHGA
43 duodenal gastrinoma 10.3 SST CHGA
44 gastric neuroendocrine neoplasm 10.3 SST CHGA
45 gastric hemangioma 10.3 SST CHGA
46 appendix lymphoma 10.3 SST CHGA
47 breast juvenile papillomatosis 10.3 GNAS BRCA2
48 glucagonoma 10.3 SST CHGA
49 pancreatic gastrinoma 10.3 SST CHGA
50 somatization disorder 10.3 POMC CRH

Graphical network of the top 20 diseases related to Pituitary Carcinoma:



Diseases related to Pituitary Carcinoma

Symptoms & Phenotypes for Pituitary Carcinoma

Human phenotypes related to Pituitary Carcinoma:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pituitary carcinoma 58 31 obligate (100%) Obligate (100%) HP:0011763
2 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
3 pituitary prolactin cell adenoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0006767
4 malignant neoplasm of the central nervous system 58 31 hallmark (90%) Very frequent (99-80%) HP:0100836
5 increased circulating acth level 58 31 hallmark (90%) Very frequent (99-80%) HP:0003154
6 increased circulating prolactin concentration 58 31 hallmark (90%) Very frequent (99-80%) HP:0000870
7 pituitary corticotropic cell adenoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0008291
8 hemianopia 58 31 frequent (33%) Frequent (79-30%) HP:0012377
9 hypopituitarism 58 31 frequent (33%) Frequent (79-30%) HP:0040075
10 progressive visual field defects 58 31 frequent (33%) Frequent (79-30%) HP:0007987
11 enlarged pituitary gland 58 31 frequent (33%) Frequent (79-30%) HP:0012505
12 reduced visual acuity 31 frequent (33%) HP:0007663
13 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
14 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
15 growth hormone excess 58 31 occasional (7.5%) Occasional (29-5%) HP:0000845
16 pituitary growth hormone cell adenoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0011760
17 spinal cord lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0100561
18 diabetes insipidus 58 31 very rare (1%) Very rare (<4-1%) HP:0000873
19 pituitary gonadotropic cell adenoma 58 31 very rare (1%) Very rare (<4-1%) HP:0011759
20 pituitary thyrotropic cell adenoma 58 31 very rare (1%) Very rare (<4-1%) HP:0011762
21 mildly reduced visual acuity 58 Frequent (79-30%)
22 hyperpituitarism 58 Occasional (29-5%)
23 abnormality of central motor function 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Pituitary Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 BRCA2 CHGA CRH GFAP GHRH GNAS
2 behavior/neurological MP:0005386 10.2 BRCA2 CRH GFAP GHRH GNAS POMC
3 endocrine/exocrine gland MP:0005379 10.14 BRCA2 CHGA CRH GHRH GNAS MGMT
4 immune system MP:0005387 10.06 BRCA2 CRH GFAP GHRH GNAS PMS2
5 digestive/alimentary MP:0005381 9.98 BRCA2 GFAP PMS2 SST SSTR2 THRB
6 liver/biliary system MP:0005370 9.8 CRH GHRH GNAS PMS2 POMC PRL
7 nervous system MP:0003631 9.77 BRCA2 CHGA CRH GFAP GHRH GNAS
8 neoplasm MP:0002006 9.76 BRCA2 GNAS MGMT PMS2 POMC PRL
9 no phenotypic analysis MP:0003012 9.23 CHGA CRH GNAS MGMT POMC SST

Drugs & Therapeutics for Pituitary Carcinoma

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Withdrawn NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
2 PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France) Unknown status NCT02854228

Search NIH Clinical Center for Pituitary Carcinoma

Genetic Tests for Pituitary Carcinoma

Anatomical Context for Pituitary Carcinoma

MalaCards organs/tissues related to Pituitary Carcinoma:

40
Pituitary, Thyroid, Spinal Cord, Lymph Node, Prostate, Endothelial

Publications for Pituitary Carcinoma

Articles related to Pituitary Carcinoma:

(show top 50) (show all 282)
# Title Authors PMID Year
1
Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment? 61
33112279 2021
2
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. 61
33427689 2020
3
Clinical features and their course of pituitary carcinoma with distant metastasis in a dog. 61
33028750 2020
4
Pituitary Adenomas with Changing Phenotype: A Systematic Review. 61
32289831 2020
5
Pituitary carcinomas: review of the current literature and report of atypical case. 61
30836020 2020
6
Results and predictors of outcome of endoscopic endonasal surgery in Cushing's disease: 20-year experience of an Italian referral Pituitary Center. 61
32215861 2020
7
Inhibition of lncRNA-UCA1 suppresses pituitary cancer cell growth and prolactin (PRL) secretion via attenuating glycolysis pathway. 61
32909148 2020
8
CAUTION ADVISED USING COMBINATION KETOCONAZOLE AND PD-1 INHIBITORS. 61
32984529 2020
9
Multimodal therapy in aggressive pituitary tumors. 61
31740190 2020
10
Cervical Nodal Metastatic Pituitary Carcinoma: A Case Report. 61
32744903 2020
11
Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases. 61
32622369 2020
12
Metastatic Pituitary Carcinoma Causing Cord Compression. 61
32289505 2020
13
Pituitary surgery's epidemiology using a national inpatient database in Japan. 61
32125502 2020
14
Newer Concepts in the Classification of Pituitary Adenomas. 61
32611886 2020
15
A Population-Level Analysis of Pituitary Carcinoma from the National Cancer Database. 61
32206537 2020
16
Aggressive prolactinomas: how to manage? 61
31617128 2020
17
Pituitary carcinoma: Two case reports and review of literature. 61
32133278 2020
18
Pituitary tumours - a large retrospective single-centre study of over 2300 cases. Experience of a tertiary reference centre. 61
32154573 2020
19
Malignant Prolactinoma With Liver Metastases Masquerading as Metastatic Gastrointestinal Stromal Tumor: A Case Report and Literature Review. 61
32760348 2020
20
Contemporary Management of Clinically Non-functioning Pituitary Adenomas: A Clinical Review. 61
32636692 2020
21
Roles of follicle stimulating hormone and its receptor in human metabolic diseases and cancer. 61
32774689 2020
22
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. 61
33312158 2020
23
[The effectiveness of risk stratification systems in diagnosis of nodular thyroid disorders]. 61
32202723 2019
24
Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors. 61
31929698 2019
25
Extraordinary case presentations in pediatric pituitary adenoma: report of 6 cases. 61
31604323 2019
26
Treatment and long-term outcomes in pituitary carcinoma: a cohort study. 61
31349217 2019
27
[Pituitary carcinoma: is it too late?] 61
31497872 2019
28
Nelson-Salassa Syndrome Progressing to Pituitary Carcinoma: A Case Report and Review of the Literature. 61
31700708 2019
29
Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. 61
31267325 2019
30
An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. 61
30706322 2019
31
Matrine inhibits the proliferation of pituitary tumor cells by decreasing Foxo3a phosphorylation and promoting Foxo3a nuclear localization. 61
30988763 2019
32
Xenoestrogen interference with nongenomic signaling actions of physiological estrogens in endocrine cancer cells. 61
30012504 2019
33
Long-Term Survival After Transformation of an Adrenocorticotropic Hormone-Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma. 61
30447452 2019
34
Evaluation of the potential of the Ki67 index to predict tumor evolution in patients with pituitary adenoma. 61
31933748 2019
35
Downregulation of glucose‑6‑phosphate dehydrogenase by microRNA‑1 inhibits the growth of pituitary tumor cells. 61
30272333 2018
36
Pathological Findings in the Pituitary Glands of Dogs and Cats. 61
29929454 2018
37
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. 61
30085142 2018
38
Neuro-Ophthalmic Manifestations of Pituitary Carcinoma. 61
29315125 2018
39
Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. 61
29404894 2018
40
Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant? 61
29318507 2018
41
Combined modalities of surgery, radiotherapy, radiosurgery and chemotherapy for invasive pituitary carcinoma. 61
29525560 2018
42
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). 61
29299820 2018
43
MicroRNA‑16/VEGFR2/p38/NF‑κB signaling pathway regulates cell growth of human pituitary neoplasms. 61
29399695 2018
44
MicroRNAs and Target Genes in Pituitary Adenomas. 61
29351706 2018
45
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. 61
29046323 2018
46
Prolactin Secreting Pituitary Carcinoma with Extracranial Spread Presenting with Pathological Fracture of Femur. 61
29456370 2018
47
Identification of Novel Genes Involved in the Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature Review. 61
30460199 2018
48
A Case of Pituitary Carcinoma Initially Diagnosed as an Ectopic Growth Hormone Producing Pituitary Adenoma with a High Ki-67 Labeling Index. 61
28586933 2018
49
Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review. 61
29928263 2018
50
Pituitary Carcinoma in a Patient with an SDHB Mutation. 61
28284009 2017

Variations for Pituitary Carcinoma

ClinVar genetic disease variations for Pituitary Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PMS2 NM_000535.7(PMS2):c.137G>T (p.Ser46Ile) SNV Likely pathogenic 9245 rs121434629 7:6045549-6045549 7:6005918-6005918
2 BRCA2 NM_000059.4(BRCA2):c.4850G>A (p.Ser1617Asn) SNV Uncertain significance 37928 rs397507341 13:32913342-32913342 13:32339205-32339205

Expression for Pituitary Carcinoma

Search GEO for disease gene expression data for Pituitary Carcinoma.

Pathways for Pituitary Carcinoma

GO Terms for Pituitary Carcinoma

Cellular components related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 SST PRL POMC MUC1 MIR93 GHRH
2 secretory granule GO:0030141 9.13 POMC CHGA BRCA2

Biological processes related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 female pregnancy GO:0007565 9.5 PRL GNAS CRH
2 positive regulation of cAMP-mediated signaling GO:0043950 9.37 GNAS CRH
3 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.26 TP53 MUC1
4 hormone-mediated apoptotic signaling pathway GO:0008628 9.16 SST CRH
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 TP53 MUC1 BRCA2
6 response to drug GO:0042493 9.1 TP53 SST PMS2 MGMT GNAS CRH

Molecular functions related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 SST PRL POMC GHRH CRH
2 corticotropin-releasing hormone receptor 1 binding GO:0051430 8.96 GNAS CRH

Sources for Pituitary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....